Posts tagged with ‘arfolitixorin’

  • 55 % Overall Response Rate on the safety extension cohorts of the ISO-CC-005 Phase I/IIa study

    GOTHENBURG, Sweden, September 30, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today provided an…

    by

  • Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin

    GOTHENBURG, Sweden, June 25, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced approval of a…

    by

  • Isofol Reports Early Tumor Shrinkage in Patients with Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin

    GOTHENBURG, Sweden, January 17, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced positive results from…

    by

  • Redeye and Isofol are inviting to the live broadcast of pre-ASCO on May 28th

    In connection to this year's major cancer congress ASCO (American Society of Clinical Oncology (https://www.asco.org/)) in Chicago in June, Redeye brings…

    by

  • Isofol announces that an abstract with new research resultshas been published for this year’s ASCO congress in Chicago

    Isofol Medical AB (publ) announces that a scientific abstract has been published for this year's annual Congress of the American…

    by

  • Isofol Medical adopts the World Health Organization recommended name (INN) arfolitixorin for Modufolin®

    Isofol Medical AB (publ) today announce that the company will in the future be adopting the generic name arfolitixorin for…

    by

  • Isofol reports successful outcome from the scientific advice with the EMA

    Isofol Medical AB (publ) has received positive feedback in scientific advice from the European Medicines Agency (EMA) regarding its candidate…

    by